Abstract
Pharmacological agents, such as histamine H2 receptor antagonists and acid pump inhibitors, are now the most frequently used treatment for such acid-related diseases as gastroduodenal ulcers and reflux esophagitis. Based on increased understanding of the precise mechanisms of gastric acid secretion at the level of receptors, enzymes, and cytoplasmic signal transduction systems, further possibilities exist for the development of effective antisecretory pharmacotherapy. Gastrin CCK2 receptor antagonists and locally active agents appear to represent promising therapies for the future. Development of gene targeting techniques has allowed production of genetically engineered transgenic and knockout mice. Such genetic technology has increased the investigative power for pharmacotherapy for not only antisecretory agents, but also treatment of mucosal diseases, such as atrophy, hyperplasia, and cancer. Elucidation of the origin of gastric parietal cells also represents an interesting investigative target that should allow a better understanding of not only acid-related diseases, but also the evolution of the stomach as an acid-secreting organ.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 109-127 |
| Number of pages | 19 |
| Journal | Pharmacology and Therapeutics |
| Volume | 98 |
| Issue number | 1 |
| DOIs | |
| State | Published - Apr 1 2003 |
| Externally published | Yes |
Fingerprint
Keywords
- Gastric acid secretion
- Gastrin/CCK receptor
- H receptor
- Histidine decarboxylase
- M receptor
- Ulcer disease
ASJC Scopus subject areas
- Pharmacology
- Pharmacology (medical)
Cite this
Pharmacological control of gastric acid secretion for the treatment of acid-related peptic disease : Past, present, and future. / Aihara, Takeshi; Nakamura, Eiji; Amagase, Kikuko; Tomita, Kazuyoshi; Fujishita, Teruaki; Furutani, Kazuharu; Okabe, Susumu.
In: Pharmacology and Therapeutics, Vol. 98, No. 1, 01.04.2003, p. 109-127.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Pharmacological control of gastric acid secretion for the treatment of acid-related peptic disease
T2 - Past, present, and future
AU - Aihara, Takeshi
AU - Nakamura, Eiji
AU - Amagase, Kikuko
AU - Tomita, Kazuyoshi
AU - Fujishita, Teruaki
AU - Furutani, Kazuharu
AU - Okabe, Susumu
PY - 2003/4/1
Y1 - 2003/4/1
N2 - Pharmacological agents, such as histamine H2 receptor antagonists and acid pump inhibitors, are now the most frequently used treatment for such acid-related diseases as gastroduodenal ulcers and reflux esophagitis. Based on increased understanding of the precise mechanisms of gastric acid secretion at the level of receptors, enzymes, and cytoplasmic signal transduction systems, further possibilities exist for the development of effective antisecretory pharmacotherapy. Gastrin CCK2 receptor antagonists and locally active agents appear to represent promising therapies for the future. Development of gene targeting techniques has allowed production of genetically engineered transgenic and knockout mice. Such genetic technology has increased the investigative power for pharmacotherapy for not only antisecretory agents, but also treatment of mucosal diseases, such as atrophy, hyperplasia, and cancer. Elucidation of the origin of gastric parietal cells also represents an interesting investigative target that should allow a better understanding of not only acid-related diseases, but also the evolution of the stomach as an acid-secreting organ.
AB - Pharmacological agents, such as histamine H2 receptor antagonists and acid pump inhibitors, are now the most frequently used treatment for such acid-related diseases as gastroduodenal ulcers and reflux esophagitis. Based on increased understanding of the precise mechanisms of gastric acid secretion at the level of receptors, enzymes, and cytoplasmic signal transduction systems, further possibilities exist for the development of effective antisecretory pharmacotherapy. Gastrin CCK2 receptor antagonists and locally active agents appear to represent promising therapies for the future. Development of gene targeting techniques has allowed production of genetically engineered transgenic and knockout mice. Such genetic technology has increased the investigative power for pharmacotherapy for not only antisecretory agents, but also treatment of mucosal diseases, such as atrophy, hyperplasia, and cancer. Elucidation of the origin of gastric parietal cells also represents an interesting investigative target that should allow a better understanding of not only acid-related diseases, but also the evolution of the stomach as an acid-secreting organ.
KW - Gastric acid secretion
KW - Gastrin/CCK receptor
KW - H receptor
KW - Histidine decarboxylase
KW - M receptor
KW - Ulcer disease
UR - http://www.scopus.com/inward/record.url?scp=0037377569&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0037377569&partnerID=8YFLogxK
U2 - 10.1016/S0163-7258(03)00015-9
DO - 10.1016/S0163-7258(03)00015-9
M3 - Review article
C2 - 12667890
AN - SCOPUS:0037377569
VL - 98
SP - 109
EP - 127
JO - Pharmacology and Therapeutics
JF - Pharmacology and Therapeutics
SN - 0163-7258
IS - 1
ER -